Phio Pharmaceuticals Corp. Annual Report: A Look for Investors

Phio Pharmaceuticals Corp. is an early-stage biotechnology company striving to revolutionize cancer treatment. This summary distills their latest annual report, providing essential insights for investors considering this high-risk, high-reward opportunity.

Business Overview: Early-Stage Immuno-Oncology Phio Pharmaceuticals is a clinical-stage biotechnology company developing new cancer immunotherapies. Their core strategy uses INTASYL™ technology to boost the body's immune system against cancer. Investors must understand that this technology and its potential medicines are in early development and remain unproven. There is no guarantee they will become approved or marketable products.

Financial Performance As a clinical-stage biotechnology company, Phio Pharmaceuticals generates no revenue from product sales. It has consistently reported, and expects to continue reporting, significant net losses. These losses stem from substantial research and development (R&D) expenses and general administrative costs. Phio's financial health depends entirely on external funding to advance its pipeline, not product sales.

Financial Health: Capital Resources and Liquidity Phio Pharmaceuticals relies heavily on external funding to advance its research and development. The company actively raised capital through multiple financing rounds in 2024 and 2025 (specifically May, July, December 2024, and January, July, November 2025). These financings often included the issuance of warrants, which can cause dilution – meaning existing shareholders own a smaller percentage of the company as more shares are issued. As of March 2, 2026, Phio had approximately 11.6 million shares of Common Stock outstanding. The common stock not held by company insiders had a market value of about $11.2 million as of June 30, 2025. Phio explicitly states it "will require substantial additional funds to complete our research and development activities," highlighting its continuous need for capital to operate and advance its pipeline. The company primarily funds its capital needs through equity.

Management Discussion and Analysis Highlights Management primarily focuses on moving its INTASYL™-based product candidates through preclinical and clinical development. Research and development expenses drive the company's operating results, making up most of its operating costs as it invests in its pipeline. General and administrative expenses also contribute to Phio's net losses. Management identifies the continuous need for substantial funding as its most significant operational challenge. Without major product sales, securing this capital is crucial for the company's survival and progress. Management actively monitors its capital resources and seeks financing opportunities. Positively, Phio Pharmaceuticals has shown resilience in its cybersecurity. Despite phishing attempts, the company has not experienced any major security incidents that significantly impacted its business or finances over the past three years. This indicates effective oversight by its Audit Committee and strong security protocols.

Key Risks for Investors Investing in Phio Pharmaceuticals involves significant risks, primarily due to its early stage and the inherent challenges of drug development:

• Unproven Technology: Phio's success depends entirely on its INTASYL™ technology. This technology is still developmental and has not yet produced approved products. It carries a high risk of not proving effective or safe enough for commercialization.
• Early-Stage Development & High Failure Rate: All of Phio's potential medicines are in early stages. Drug development is a long, costly, and uncertain process with a high failure rate. Products may never reach clinical trials or may fail during them.
• Clinical Trial Challenges: Difficulties finding and enrolling enough suitable patients for clinical trials can cause significant delays. Also, initial 'topline data' (early results) from trials might not always reflect final outcomes, leading to potential disappointments.
• Regulatory Hurdles: Regulatory bodies like the FDA have stringent approval processes, which external factors can impact. Disruptions at the FDA, such as staff reductions or funding issues, could slow product approvals, affecting Phio's timelines and market entry.
• Manufacturing Dependence: Phio relies on third-party manufacturers for its clinical supplies. Any issues or disruptions with these external partners could severely hinder Phio's development progress.
• Intellectual Property Protection: The company's business model heavily depends on its patents and licensed technologies. Failure to maintain these patents or secure rights to critical technologies could undermine its ability to develop and commercialize products.
• Crucial Funding Needs & Dilution: As noted, Phio requires 'substantial additional funds.' If the company cannot secure this capital, or must do so by issuing many new shares, it could significantly dilute existing shareholder investments.
• Cybersecurity Threats: While Phio has managed past threats, the evolving nature of cyber risks means future attacks could still compromise data or operations, despite current safeguards.

Future Outlook and Strategy Phio Pharmaceuticals' immediate future centers on securing the 'substantial additional funds' needed to continue its research and development. The company's strategy involves advancing its lead product candidates through preclinical and clinical development. It aims for key milestones like filing Investigational New Drug (IND) applications, starting clinical trials, and generating clinical data. Phio plans to progress its current drug development programs, acknowledging the long and challenging journey from early-stage research to potential market approval.

Competitive Position The biotechnology industry, especially immuno-oncology, is highly competitive, marked by rapid technological change and intense research and development. Phio Pharmaceuticals competes with a broad range of organizations, including large pharmaceutical companies, other biotech firms, and academic institutions developing or commercializing cancer therapies. Many of these competitors possess significantly greater financial, technical, and human resources than Phio. Phio aims for its proprietary INTASYL™ technology to be its competitive advantage. This technology seeks to differentiate its potential medicines by offering a new way to boost the body's immune response against cancer. Phio's ability to compete effectively will depend on successfully developing and commercializing its product candidates, securing and maintaining patent protection, and attracting and retaining skilled personnel.

Conclusion Phio Pharmaceuticals presents a high-risk, potentially high-reward investment opportunity, typical of early-stage biotech companies. Its future success hinges on validating its INTASYL™ technology, achieving successful clinical development, and consistently securing significant funding without excessive dilution.